Literature DB >> 7767529

Cyclosporine A decreases rat skeletal muscle mitochondrial respiration in vitro.

J F Hokanson1, J G Mercier, G A Brooks.   

Abstract

Cyclosporine A (CsA) is a potent immunosuppressant used to decrease organ rejection after transplantation surgery. Reported limitations to use of CsA have been hepatotoxicity and nephrotoxicity. Additionally, exercise capacity is much less than expected following transplantation even if arterial oxygen transport capacity is repaired. Purposes of the present study were to determine the effects of CsA on skeletal muscle mitochondrial respiration in vitro and to determine the site of the CsA skeletal muscle mitochondrial lesion. Mitochondria were isolated from rat hind limb muscle homogenates after differential centrifugation. Mitochondrial respiration was determined using a Rank oxygen polarograph at 37 degrees C in a sucrose and mannitol respiration medium. CsA inhibited maximal respiration (ADP stimulated) in the presence of succinate and rotenone by 18.3% and in the presence of malate and pyruvate by 34.7%. CsA decreased the rate of uncoupled respiration (addition of carbonyl cyanide p-trifluoromethozyphenylhydrazone) by 19.6% and 32.0% for succinate and rotenone, or pyruvate plus malate, respectively. No significant effect of CsA on ADP/O for either substrate was observed. We conclude that CsA inhibits maximal coupled and uncoupled skeletal muscle mitochondrial respiration in vitro. Moreover, although the effects of CsA were greater on electron flux through Complex I, mitochondrial lesions caused by CsA were not specific to either Complex I or Complex II of the electron transport chain (ETC). Poor exercise performance despite adequate arterial oxygenation and systemic and regional oxygen deliveries in transplant patients may be attributed, in part, to the effects of immunosuppressive therapy on ETC capacity of skeletal muscle mitochondria.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7767529     DOI: 10.1164/ajrccm.151.6.7767529

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  7 in total

1.  Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain.

Authors:  H Sanchez; J Zoll; X Bigard; V Veksler; B Mettauer; E Lampert; J Lonsdorfer; R Ventura-Clapier
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Preferential reduction of quadriceps over respiratory muscle strength and bulk after lung transplantation for cystic fibrosis.

Authors:  C Pinet; P Scillia; M Cassart; M Lamotte; C Knoop; C Mélot; M Estenne
Journal:  Thorax       Date:  2004-09       Impact factor: 9.139

3.  Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells.

Authors:  K L Abbott; B B Friday; D Thaloor; T J Murphy; G K Pavlath
Journal:  Mol Biol Cell       Date:  1998-10       Impact factor: 4.138

4.  Exercise limitations in a competitive cyclist twelve months post heart transplantation.

Authors:  Jeremy A Patterson; Nicolas G Walton
Journal:  J Sports Sci Med       Date:  2009-12-01       Impact factor: 2.988

5.  Cyclosporin A aggravates hydrogen peroxide-induced cell death in kidney proximal tubule epithelial cells.

Authors:  Daeun Moon; Jinu Kim
Journal:  Anat Cell Biol       Date:  2019-08-26

6.  The Effect of Endurance Training on Pulmonary V˙O2 Kinetics in Solid Organs Transplanted Recipients.

Authors:  Alessio Del Torto; Carlo Capelli; Roberto Peressutti; Adriana Di Silvestre; Ugolino Livi; Chiara Nalli; Sandro Sponga; Giampaolo Amici; Umberto Baccarani; Stefano Lazzer
Journal:  Int J Environ Res Public Health       Date:  2022-07-26       Impact factor: 4.614

7.  Physical fitness, fatigue, and quality of life after liver transplantation.

Authors:  Berbke T J van Ginneken; Rita J G van den Berg-Emons; Geert Kazemier; Herold J Metselaar; Hugo W Tilanus; Henk J Stam
Journal:  Eur J Appl Physiol       Date:  2007-03-16       Impact factor: 3.078

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.